InvestorsHub Logo
icon url

GDorn

05/19/14 9:28 PM

#168347 RE: Art Vandeley #168340

My point being:

In the court decision cited hemp products were deemed to be outside the DEA's authority because the content of a Schedule 1 compound contained in it had zero potential effect.

CNAV/MJNA/Kannway make no specific medical claims as to the effect of the CBD in the products they sell but they also do not claim is that the CBD content of what they sell is so low as to not have any possible effect (though in Kannaway's case this might be true).

CBD IS a Schedule 1 substance, again, as stupid as that may be. A court decision that legitimized hemp products as legal because they were too low in one naturally occurring Schedule 1 substance is not a good parallel to claim that products with decidedly enhanced levels of another Schedule 1 substance are also therefore legal just because they are derived from hemp.

I hope this never goes to court. I hope the legal situation is clarified by far more rational legislation and as far as that goes, Tuesday would be good for me. But that isn't the case right now. And our national drug policy has not made rational sense for many decades, making an investment decision based on the hope that it will stop making nonsense before it actually changes, well it's a risk factor.